Miraculins Hopes to Generate Up to $500K in Equity Placement | GenomeWeb
NEW YORK (GenomeWeb News) — Miraculins yesterday said it plans to generate as much as $500,000 through a private stock placement.
The company plans to use the proceeds to fund research and development projects, and for working capital purposes.
Miraculins will offer as many as 1.25 million equity “units” for $.40 apiece. Each unit will include one common company share and one half of one share purchase warrant, which will be set at $.65 for a 12-month period from the date the offering closes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.